These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24438944)

  • 1. Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
    Raps M; Curvers J; Helmerhorst FM; Ballieux BE; Rosing J; Thomassen S; Rosendaal FR; van Vliet HA
    Thromb Res; 2014 Apr; 133(4):640-4. PubMed ID: 24438944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
    Raps M; Helmerhorst FM; Fleischer K; Dahm AE; Rosendaal FR; Rosing J; Reitsma P; Sandset PM; van Vliet HA
    Thromb Haemost; 2013 Apr; 109(4):606-13. PubMed ID: 23407778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives.
    Raps M; Helmerhorst F; Fleischer K; Thomassen S; Rosendaal F; Rosing J; Ballieux B; VAN Vliet H
    J Thromb Haemost; 2012 Jun; 10(6):992-7. PubMed ID: 22469296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
    van Vliet HA; Frolich M; Christella M; Thomassen LG; Doggen CJ; Rosendaal FR; Rosing J; Helmerhorst FM
    Hum Reprod; 2005 Feb; 20(2):563-8. PubMed ID: 15539435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of various contraceptives on laboratory parameters in diagnosis of thyroid gland function with special reference to the free hormones FT4 and FT3].
    Sorger D; Schenk S; Schneider G
    Z Gesamte Inn Med; 1992 Feb; 47(2):58-64. PubMed ID: 1585690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
    van Vliet HA; Tchaikovski SN; Rosendaal FR; Rosing J; Helmerhorst FM
    Thromb Haemost; 2009 Apr; 101(4):691-5. PubMed ID: 19350113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
    Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
    Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral contraceptive pill and thrombotic risk: epidemiological studies].
    Fruzzetti F; Perini D; Spirito N; Manca R
    Minerva Ginecol; 2012 Dec; 64(6):539-49. PubMed ID: 23232538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.
    Tchaikovski SN; van Vliet HA; Thomassen MC; Bertina RM; Rosendaal FR; Sandset PM; Helmerhorst FM; Tans G; Rosing J
    Thromb Haemost; 2007 Dec; 98(6):1350-6. PubMed ID: 18064335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor.
    van Vliet HA; Bertina RM; Dahm AE; Rosendaal FR; Rosing J; Sandset PM; Helmerhorst FM
    J Thromb Haemost; 2008 Feb; 6(2):346-51. PubMed ID: 18067603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.
    Alhenc-Gelas M; Plu-Bureau G; Guillonneau S; Kirzin JM; Aiach M; Ochat N; Scarabin PY
    J Thromb Haemost; 2004 Sep; 2(9):1594-600. PubMed ID: 15333036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to activated protein C in women using oral contraceptives.
    Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
    Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal contraception and risk of venous thromboembolism: national follow-up study.
    Lidegaard Ø; Løkkegaard E; Svendsen AL; Agger C
    BMJ; 2009 Aug; 339():b2890. PubMed ID: 19679613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.
    van Hylckama Vlieg A; Helmerhorst FM; Vandenbroucke JP; Doggen CJ; Rosendaal FR
    BMJ; 2009 Aug; 339():b2921. PubMed ID: 19679614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
    Lidegaard O; Nielsen LH; Skovlund CW; Løkkegaard E
    BMJ; 2012 May; 344():e2990. PubMed ID: 22577198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives, thrombosis and haemostasis.
    Rosing J; Curvers J; Tans G
    Eur J Obstet Gynecol Reprod Biol; 2001 Apr; 95(2):193-7. PubMed ID: 11301170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renewed interest in haemostasis changes induced by oral contraceptives (OCs).
    Kluft C
    Thromb Haemost; 2000 Jul; 84(1):1-3. PubMed ID: 10928460
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study.
    Fleischer K; van Vliet HA; Rosendaal FR; Rosing J; Tchaikovski S; Helmerhorst FM
    Thromb Res; 2009; 123(3):429-35. PubMed ID: 18829069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined oral contraceptives: venous thrombosis.
    de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.